CVS Health Corporation

BRSE:CVS Stock Report

Market Cap: CHF 67.2b

CVS Health Valuation

Is CVS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CVS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 172.26
Fair Value
70.4% undervalued intrinsic discount
24
Number of Analysts

Below Fair Value: CVS (CHF51) is trading below our estimate of fair value (CHF172.26)

Significantly Below Fair Value: CVS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CVS?

Key metric: As CVS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CVS. This is calculated by dividing CVS's market cap by their current earnings.
What is CVS's PE Ratio?
PE Ratio18.3x
EarningsUS$4.53b
Market CapUS$83.13b

Price to Earnings Ratio vs Peers

How does CVS's PE Ratio compare to its peers?

The above table shows the PE ratio for CVS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.1x
ALC Alcon
37.8x12.84%CHF 34.3b
STMN Straumann Holding
35.2x13.16%CHF 16.1b
SOON Sonova Holding
24.8x10.96%CHF 13.4b
CI Cigna Group
14.6x11.04%US$72.3b
CVS CVS Health
18.3x17.79%CHF 83.1b

Price-To-Earnings vs Peers: CVS is good value based on its Price-To-Earnings Ratio (18.3x) compared to the peer average (28.1x).

Price to Earnings Ratio vs Industry

How does CVS's PE Ratio compare vs other companies in the European Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CVS 18.3xIndustry Avg. 18.5xNo. of Companies8PE01224364860+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CVS is good value based on its Price-To-Earnings Ratio (18.3x) compared to the European Healthcare industry average (19.4x).

Price to Earnings Ratio vs Fair Ratio

What is CVS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CVS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CVS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CVS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 51.00
CHF 64.83
+27.11%
9.51%CHF 79.86CHF 54.05n/a24
Aug ’26n/a
CHF 64.33
0%
8.61%CHF 76.48CHF 53.94n/a24
Jul ’26n/a
CHF 63.26
0%
7.11%CHF 75.37CHF 56.33n/a25
Jun ’26CHF 50.53
CHF 65.53
+29.69%
7.28%CHF 78.20CHF 58.44n/a25
May ’26n/a
CHF 63.58
0%
7.54%CHF 74.66CHF 55.58n/a25
Apr ’26CHF 59.65
CHF 63.70
+6.79%
11.06%CHF 75.82CHF 42.33n/a25
Mar ’26n/a
CHF 64.72
0%
13.08%CHF 82.03CHF 43.07n/a25
Feb ’26n/a
CHF 59.63
0%
16.51%CHF 84.57CHF 43.66n/a25
Jan ’26CHF 40.43
CHF 60.12
+48.72%
16.19%CHF 84.39CHF 43.56n/a25
Dec ’25n/a
CHF 60.62
0%
13.55%CHF 82.49CHF 50.56n/a25
Nov ’25CHF 50.23
CHF 60.16
+19.78%
14.45%CHF 80.56CHF 51.11n/a25
Oct ’25n/a
CHF 56.61
0%
14.02%CHF 78.42CHF 49.75n/a25
Sep ’25n/a
CHF 57.02
0%
13.04%CHF 78.84CHF 50.02n/a25
Aug ’25CHF 55.91
CHF 59.88
+7.09%
13.10%CHF 82.21CHF 51.27n/a25
Jul ’25n/a
CHF 61.08
0%
13.42%CHF 82.22CHF 52.16n/a26
Jun ’25n/a
CHF 62.27
0%
13.50%CHF 83.91CHF 53.23CHF 50.5326
May ’25n/a
CHF 77.84
0%
10.81%CHF 92.83CHF 55.15n/a26
Apr ’25n/a
CHF 79.32
0%
7.50%CHF 91.33CHF 68.28CHF 59.6526
Mar ’25n/a
CHF 79.36
0%
6.96%CHF 91.08CHF 68.09n/a25
Feb ’25CHF 64.42
CHF 78.72
+22.18%
7.39%CHF 90.30CHF 69.46n/a24
Jan ’25CHF 66.87
CHF 75.64
+13.11%
8.58%CHF 88.98CHF 65.02CHF 40.4324
Dec ’24n/a
CHF 77.69
0%
9.21%CHF 91.91CHF 67.17n/a23
Nov ’24n/a
CHF 81.88
0%
10.41%CHF 99.86CHF 68.99CHF 50.2323
Oct ’24n/a
CHF 83.74
0%
10.30%CHF 100.71CHF 69.58n/a24
Sep ’24n/a
CHF 81.78
0%
9.77%CHF 97.45CHF 67.33n/a24
Aug ’24CHF 65.77
CHF 82.54
+25.49%
12.15%CHF 105.03CHF 63.02CHF 55.9123
AnalystConsensusTarget
Consensus Narrative from 24 Analysts
CHF 62.54
Fair Value
18.4% undervalued intrinsic discount
24
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/09 16:25
End of Day Share Price 2025/08/06 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CVS Health Corporation is covered by 62 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harshit GuptaAccountability Research Corporation
Christopher GrajaArgus Research Company
Samuel HudsonAtlantic Equities LLP